Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 1/20 | 0.66 |
| ▸ | GAA | P10253 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 3/20 | 0.64 |
| ▸ | RAB9A | P51151 | 3/20 | 0.64 |
| ▸ | HPGD | P15428 | 3/20 | 0.63 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.62 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | CES2 | O00748 | 1/20 | 0.61 |
| ▸ | CES1 | P23141 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.59 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6361446 | 0.87 | GAA (0.73) | MMP13GAAMAPTNPC1RAB9A | |
| SCHEMBL11246936 | 0.85 | MMP13 (0.64) | MMP13GAAMAPTNPC1RAB9A | |
| SCHEMBL11368783 | 0.85 | MMP13 (0.64) | MMP13GAAMAPTNPC1RAB9A | |
| SCHEMBL13702271 | 0.85 | SMN1; SMN2 (0.63) | MAPTNPC1RAB9AHPGDKMT2A | |
| SCHEMBL3827918 | 0.84 | GAA (0.82) | MMP13GAAMAPTNPC1RAB9A | |
| SCHEMBL5672356 | 0.84 | HPGD (0.72) | MMP13GAAMAPTNPC1RAB9A | |
| SCHEMBL13465506 | 0.84 | KMT2A (0.60) | MMP13GAAMAPTNPC1RAB9A | |
| SCHEMBL9491894 | 0.84 | GAA (0.73) | MMP13GAAMAPTNPC1RAB9A | |
| SCHEMBL11756934 | 0.84 | GAA (0.73) | MMP13GAAMAPTNPC1RAB9A | |
| SCHEMBL3995095 | 0.84 | SMN1; SMN2 (0.52) | MMP13GAAMAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709384-A2 | COMBINATION THERAPY FOR TREATMENT OF CANCER | PMV Pharmaceuticals, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| WO-2024238404-A2 | COMBINATION THERAPY FOR TREATMENT OF CANCER | PMV PHARMACEUTICALS, INC. (US) | 2024-11-21 | — | — | WO | disclosed |
| EP-3341007-B1 | MALT1 INHIBITORS AND USES THEREOF | UNIV CORNELL (US) | 2020-12-23 | — | — | EP | disclosed |
| US-9663510-B2 | Substituted triazolopyridines and their use as TTK inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-05-30 | — | — | US | disclosed |
| US-20160120854-A1 | PHARMACEUTICAL COMPOSITIONS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-05-05 | — | — | US | disclosed |
| CN-103608350-B | Triazolopyridine compounds | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-11-25 | — | — | CN | disclosed |
| US-20150210683-A1 | SUBSTITUTED TRIAZOLOPYRIDINES AND THEIR USE AS TTK INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-07-30 | — | — | US | disclosed |
| CN-103608350-A | Triazolopyridine compounds | BAYER IP GMBH | 2014-02-26 | — | — | CN | disclosed |
| US-8273772-B2 | Heteroaryl compounds as P2Y1 receptor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-09-25 | — | — | US | disclosed |
| US-8273772-B2 | Heteroaryl compounds as P2Y1 receptor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-09-25 | — | — | US | disclosed |
| EP-2010542-A2 | 4,5-DIHYDRO-[1,2,4]TRIAZOLO[4,3-F]PTERIDINES AS PROTEIN KINASE PLK1 INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Vertex Pharmaceuticals Incorporated (US) | 2009-01-07 | — | — | EP | disclosed |
| EP-1954696-A2 | 2-PHENOXY-N-(1,3,4-THIADIZOL-2-YL)PYRIDIN-3-AMINE DERIVATIVES AND RELATED COMPOUNDS AS P2Y1 RECEPTOR INHIBITORS FOR THE TREATMENT OF THROMBOEMBOLIC DISORDERS | Bristol-Myers Squibb Company (US) | 2008-08-13 | — | — | EP | disclosed |
| US-7390830-B1 | Remedies or prophylactics for diseases in association with chemokines | TEIJIN LIMITED (JP) | 2008-06-24 | — | — | US | disclosed |
| WO-2006078621-A9 | 2-PHENOXY-N- (1, 3 , 4-THIADIZOL-2-YL) PYRIDIN-3-AMINE DERIVATIVES AND RELATED COMPOUNDS AS P2Y1 RECEPTOR INHIBITORS FOR THE TREATMENT OF THROMBOEMBOLIC DISORDERS | BRISTOL MYERS SQUIBB CO (US) | 2008-06-19 | — | — | WO | disclosed |
| WO-2006078621-A9 | 2-PHENOXY-N- (1, 3 , 4-THIADIZOL-2-YL) PYRIDIN-3-AMINE DERIVATIVES AND RELATED COMPOUNDS AS P2Y1 RECEPTOR INHIBITORS FOR THE TREATMENT OF THROMBOEMBOLIC DISORDERS | BRISTOL MYERS SQUIBB CO (US) | 2008-06-19 | — | — | WO | disclosed |
| CN-101142212-A | 2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3-amine derivatives and related compounds as p2y1 receptor inhibitors for the treatment of thromboembolic disorders | BRISTOL MYERS SQUIBB CO (US) | 2008-03-12 | — | — | CN | disclosed |
| WO-2007120752-A2 | 4, 5-DIHYDRO- [1, 2, 4] TRIAZOLO [4, 3-F] PTERIDINES AS PROTEIN KINASE PLK1 INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-25 | — | — | WO | disclosed |
| US-20060173002-A1 | Heteroaryl compounds as P2Y1 receptor inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-08-03 | — | — | US | disclosed |
| WO-2006078621-A2 | 2-PHENOXY-N- (1, 3 , 4-THIADIZOL-2-YL) PYRIDIN-3-AMINE DERIVATIVES AND RELATED COMPOUNDS AS P2Y1 RECEPTOR INHIBITORS FOR THE TREATMENT OF THROMBOEMBOLIC DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-07-27 | — | — | WO | disclosed |
| US-5977132-A | GALACTORRHEA, HYPERPROLACTINEMIC OVULATION, PROLACTINOMA AND BRAIN TUMORS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173002-A1 | Heteroaryl compounds as P2Y1 receptor inhibitors | P2RY1, P2RY11, P2RY2 | MMP13 4771/4885GAA 2336/4885MAPT 4566/4885 |
| US-20150210683-A1 | SUBSTITUTED TRIAZOLOPYRIDINES AND THEIR USE AS TTK INHIBITORS | TTK, TXK, ITK | MMP13 4662/4885GAA 701/4885MAPT 2326/4885 |
| US-20160120854-A1 | PHARMACEUTICAL COMPOSITIONS | CYP3A5, CYP2C19, CYP3A7 | MMP13 4550/4885GAA 348/4885MAPT 1832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.